Effect of abiraterone versus docetaxel in patients with Castration-Resistant Prostate Cancer

Trial Profile

Effect of abiraterone versus docetaxel in patients with Castration-Resistant Prostate Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Abiraterone (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 May 2017 Results (n=303) presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 01 Jun 2015 New trial record
    • 20 May 2015 Results presented at the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top